Cargando…

Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review

Radiation therapy and systemic therapy are the primary non-surgical treatment modalities for head and neck squamous cell carcinoma (HNSCC). Despite advances in our biologic understanding of this disease and the development of novel therapeutics, treatment resistance remains a significant problem. It...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayman, Thomas J., Bhatia, Aarti K., Jethwa, Krishan R., Young, Melissa R., Park, Henry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Synergy in Action: Novel Approaches to Combining Radiation Therapy and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798834/ https://www.ncbi.nlm.nih.gov/pubmed/35116571 http://dx.doi.org/10.21037/tcr-20-2096

Ejemplares similares

Immunotherapy and radiation for high-grade glioma: a narrative review
por: Fakhoury, Kareem R., et al.
Publicado: (2021)

Narrative review of immunotherapy and radiation therapy in elderly patients
por: Chau, Brittney, et al.
Publicado: (2021)

A narrative review of combining radiation and immunotherapy in gastroesophageal cancers
por: Yoon, Kevin, et al.
Publicado: (2021)

The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review
por: Heinzerling, John H., et al.
Publicado: (2021)

Radiation and immunotherapy: united as one in the fight against cancer
por: Amini, Arya, et al.
Publicado: (2021)

Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases
por: Moskalenko, Marina, et al.
Publicado: (2021)

Combination radiation and immunotherapy in gynecologic malignancies—a comprehensive review
por: Ladbury, Colton, et al.
Publicado: (2021)

Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
por: Jin, Xuan, et al.
Publicado: (2020)

Comparison of efficacy and safety between third‐dose triple and third‐dose dual antihypertensive combination therapies in patients with hypertension
por: Sung, Ki‐Chul, et al.
Publicado: (2023)

Cardiovascular outcomes of β‐blocker—calcium channel blocker initial dual therapy vs. other initial dual therapies in Chinese patients with hypertension: A real‐world retrospective study
por: Lin, Junxiong, et al.
Publicado: (2023)

Age‐specific differences in hypertension combination management and associated factors influencing treatment choice
por: Xiong, Jianfei, et al.
Publicado: (2023)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
por: Rajeev-Kumar, Greeshma, et al.
Publicado: (2022)

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review
por: Liu, Jason, et al.
Publicado: (2023)

Interleukin-6 role in head and neck squamous cell carcinoma progression
por: Choudhary, Moaz M., et al.
Publicado: (2016)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

Toxicity of radiation and immunotherapy combinations
por: Verma, Vivek, et al.
Publicado: (2018)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Immunotherapy in head and neck squamous cell carcinoma: a narrative review
por: Sharon, Shay, et al.
Publicado: (2022)

High risk cutaneous squamous cell carcinoma of the head and neck
por: Kang, Stephen Y., et al.
Publicado: (2016)

The DNA damage response in immunotherapy and radiation
por: Samstein, Robert M., et al.
Publicado: (2018)

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
por: Coppock, Joseph D., et al.
Publicado: (2016)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Exploring optimal sequencing of radiation and immunotherapy combinations
por: Gunderson, Andrew J., et al.
Publicado: (2018)

Introduction to the special edition on immunotherapy and radiation oncology
por: Bornstein, Sophia, et al.
Publicado: (2018)

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

Novel p53 therapies for head and neck cancer
por: Castellanos, Mario R., et al.
Publicado: (2016)

Radiosensitization approaches for HPV‐positive and HPV‐negative head and neck squamous carcinomas
por: Dok, Rüveyda, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes
por: Tatovic, D, et al.
Publicado: (2022)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer
por: Góra, Joanna, et al.
Publicado: (2013)

Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma
por: Mimikos, Christina, et al.
Publicado: (2016)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years
por: Yao, Jiajia, et al.
Publicado: (2023)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model
por: Wang, Jie, et al.
Publicado: (2022)

Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients – Knowledge from two independent international studies
por: Zhou, Jian-Guo, et al.
Publicado: (2023)

Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions
por: Kim, Yejin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o8t9qqj3228dppfc80vv8hbjdm